Nurix Therapeutics Announces Material Definitive Agreement
Ticker: NRIX · Form: 8-K · Filed: Apr 12, 2024 · CIK: 1549595
Sentiment: neutral
Topics: material-definitive-agreement, filing
TL;DR
Nurix inked a big deal, filing an 8-K on 4/11. Big news incoming.
AI Summary
On April 11, 2024, Nurix Therapeutics, Inc. announced a material definitive agreement, indicating a significant development for the company. The filing also includes other events and financial statements, with the report being filed on April 12, 2024.
Why It Matters
This filing signals a potentially significant business transaction or partnership for Nurix Therapeutics, which could impact its future growth and stock performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, making the immediate impact on the company's risk profile uncertain.
Key Players & Entities
- Nurix Therapeutics, Inc. (company) — Registrant
- April 11, 2024 (date) — Date of Earliest Event Reported
- April 12, 2024 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
- 1700 Owens Street, Suite 205 (address) — Principal Executive Offices
- San Francisco, California (location) — Principal Executive Offices City and State
- 94158 (zip_code) — Principal Executive Offices Zip Code
- (415) 660-5320 (phone_number) — Registrant's Telephone Number
FAQ
What is the nature of the material definitive agreement announced by Nurix Therapeutics?
The filing does not specify the details of the material definitive agreement, only that one has been entered into as of April 11, 2024.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted on April 12, 2024.
What is Nurix Therapeutics' principal executive office address?
Nurix Therapeutics' principal executive offices are located at 1700 Owens Street, Suite 205, San Francisco, California, 94158.
What is the company's telephone number?
The company's telephone number is (415) 660-5320.
What is the SIC code for Nurix Therapeutics?
The Standard Industrial Classification (SIC) code for Nurix Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,282 words · 5 min read · ~4 pages · Grade level 11 · Accepted 2024-04-12 17:12:05
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share NRIX Nasdaq Glo
- $15.00 — be sold at the public offering price of $15.00 per Share. The Pre-Funded Warrants will
- $14.999 — l be sold at a public offering price of $14.999 per Pre-Funded Warrant, which represent
- $164.0 m — from the Offering will be approximately $164.0 million, after deducting underwriting dis
Filing Documents
- d818273d8k.htm (8-K) — 32KB
- d818273dex11.htm (EX-1.1) — 280KB
- d818273dex41.htm (EX-4.1) — 60KB
- d818273dex51.htm (EX-5.1) — 18KB
- d818273dex991.htm (EX-99.1) — 9KB
- g818273g0412071557368.jpg (GRAPHIC) — 2KB
- g818273page1a.jpg (GRAPHIC) — 10KB
- g818273page1c.jpg (GRAPHIC) — 9KB
- g818273page2b.jpg (GRAPHIC) — 9KB
- 0001193125-24-094875.txt ( ) — 651KB
- nrix-20240411.xsd (EX-101.SCH) — 3KB
- nrix-20240411_lab.xml (EX-101.LAB) — 18KB
- nrix-20240411_pre.xml (EX-101.PRE) — 11KB
- d818273d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements relating to the expected net proceeds of the Offering, the anticipated use of proceeds of the Offering, and the timing of the closing of the Offering, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks identified in the Company's filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, the prospectus supplements related to the Offering, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect the Company's results of operations, which would, in turn, have a significant and adverse impact on the Company's stock price. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NURIX THERAPEUTICS, INC. By: /s/ Christine Ring Christine Ring, Ph.D., J.D. Chief Legal Officer and Chief Compliance Officer Date: April 12, 2024